N※N

BioMedisys Develops Painless Glucose Monitoring

  //science-technology.news-articles.net/content/2 .. edisys-develops-painless-glucose-monitoring.html
  Published in Science and Technology on Friday, February 6th 2026 at 2:17 GMT by CultureMap San Antonio
      Locales: Texas, UNITED STATES

SAN ANTONIO, TX - February 6th, 2026 - BioMedisys, a San Antonio-based biotechnology firm, is poised to redefine diabetes care with its groundbreaking non-invasive glucose monitoring technology. After a decade of research and development, the company is rapidly advancing towards commercialization of a wearable sensor capable of accurately measuring glucose levels through the skin, promising to alleviate the discomfort and inconvenience associated with traditional methods.

The current standard of care for most individuals with diabetes involves frequent finger-prick blood tests or the use of continuous glucose monitors (CGMs). While CGMs offer more frequent readings, they require insertion of a small sensor under the skin, which can cause discomfort, irritation, and even infection. BioMedisys's innovation aims to overcome these limitations by utilizing a completely external, painless approach.

"We've listened to the patients, and the feedback was clear: the existing solutions, while functional, are far from ideal," explains Robert Waggoner, CEO of BioMedisys. "The daily ritual of finger pricks is painful and disruptive. CGMs, while better, still pose challenges in terms of comfort and usability. We're striving for a truly patient-centric solution - something that integrates seamlessly into daily life without adding burden."

BioMedisys's sensor operates on the principle of measuring glucose levels in the interstitial fluid - the fluid that surrounds cells. A minuscule, imperceptible electrical current is applied to the skin, and the resulting data is analyzed to determine glucose concentration. This data is then wirelessly transmitted to a user's smartphone or other connected device, providing real-time glucose readings and trends.

The potential benefits of this technology extend beyond mere convenience. Preliminary studies suggest the BioMedisys sensor may offer improved accuracy compared to existing methods, particularly in detecting rapid glucose fluctuations. This enhanced precision is crucial for individuals managing diabetes, allowing for more informed insulin dosage adjustments and proactive prevention of hypo- or hyperglycemia.

Beyond Monitoring: The Vision of a Closed-Loop System

BioMedisys's long-term vision doesn't stop at glucose monitoring. The company is actively developing a fully integrated closed-loop system that combines the non-invasive sensor with a micro-insulin delivery device. This 'artificial pancreas' would automatically adjust insulin levels based on real-time glucose readings, effectively mimicking the function of a healthy pancreas.

"The holy grail in diabetes management is achieving true glycemic control with minimal patient effort," Waggoner states. "A closed-loop system powered by our sensor has the potential to dramatically improve the quality of life for millions of people living with diabetes, reducing the risk of long-term complications and empowering them to live fuller, healthier lives."

A Decade of Dedication & Significant Investment

Founded in 2016, BioMedisys has steadily built its reputation as a leader in non-invasive monitoring technologies. The company's commitment to innovation has attracted substantial investment, most recently culminating in a $10 million Series A funding round in late 2025. This capital injection will be instrumental in accelerating the final stages of development, including large-scale clinical trials and regulatory approvals.

The Series A funding was led by venture capital firm HealthTech Innovations, with participation from several angel investors specializing in medical devices and digital health. Analysts predict that the success of BioMedisys could attract further investment and potentially lead to acquisition by a larger pharmaceutical or medical device company.

The Broader Implications for Personalized Medicine

The impact of BioMedisys's technology extends beyond diabetes. The company's underlying sensor platform has the potential to be adapted for monitoring a wide range of biomarkers, paving the way for truly personalized medicine. Imagine a future where wearable sensors can continuously track key health indicators, providing early warnings of disease onset and enabling proactive interventions.

"We believe that non-invasive monitoring is the future of healthcare," concludes Waggoner. "By providing real-time, personalized data, we can empower individuals to take control of their health and live longer, healthier lives. BioMedisys is not just building a medical device; we're building a platform for a more proactive and preventative healthcare system."

BioMedisys is currently preparing to initiate multi-center clinical trials in early 2026 and anticipates submitting its sensor for FDA approval by the end of the year. The company aims to have its product commercially available in select markets by 2027.